Alaunos Therapeutics Reports Promising Preclinical Data for Non-Hormonal Obesity Drug ALN1003
核心洞察
Alaunos Therapeutics announced positive preclinical results for ALN1003 (搜索), showing up to 12.9% body weight reduction in diet-induced obesity (搜索) mouse models.
The oral small-molecule drug demonstrated significant liver weight reductions of up to 55% and improvements in liver injury biomarkers compared to controls.
ALN1003 (搜索) offers a differentiated non-hormonal approach to obesity (搜索) treatment, potentially providing an alternative to current hormone-based therapies like GLP-1 drugs.
Alaunos Therapeutics has reported encouraging preclinical data for ALN1003 (搜索), its lead oral small-molecule candidate for treating obesity (搜索) and metabolic dysfunction-associated steatotic liver disease (搜索) (MASLD (搜索)). The biotechnology company announced results from two non-Good Laboratory Practice diet-induced obesity mouse studies that demonstrated dose-dependent weight loss and favorable metabolic changes.
Significant Weight Loss and Metabolic Improvements
In the first study, ALN1003 (搜索)-treated mice achieved a peak body weight reduction of 12.9% (p<0.0001) on Day 34 compared to diet-induced obesity (搜索) controls, maintaining a 10.3% reduction (p<0.0001) after 48 days of treatment. The drug also reduced cumulative food consumption from 425.0 g/cage in controls to 347.5 g/cage in treated animals (nominal p<0.05).
The second pilot study evaluated three dose levels over 14 days and revealed dose-dependent effects on body composition. Using a Bruker MinispecTM LF90II Body Composition Analyzer, researchers observed that weight loss was driven primarily by fat reduction, with the highest dose group showing a 44.6% decrease in fat mass (p<0.0001) and a 21.9% reduction in fat as a percentage of body weight (p<0.0001).
Liver-Related Benefits
ALN1003 (搜索) demonstrated substantial liver-related improvements across both studies. In the first study, the drug reduced liver weight by 43% (p<0.0001) compared to untreated mice and by 39% when expressed as a percentage of body weight (p<0.0001). Long-term administration was associated with significant reductions in liver injury enzymes, including ALT (p<0.0001), AST (nominal p<0.0001), and ALP (p<0.0001).
The second study showed dose-related liver weight reductions of 6.8%, 20.5%, and 55.0% (nominal p<0.01) in low, medium, and high dose groups, respectively. Macroscopic examination revealed smaller, deep reddish-brown livers with reduced visible fat accumulation compared to controls.
Metabolic Parameter Improvements
The highest-dose group in the second study demonstrated significant improvements in key metabolic markers. Blood glucose levels decreased from 320 mg/dL in controls to 197 mg/dL (p<0.0001), while total cholesterol dropped from 209 mg/dL to 162 mg/dL (nominal p<0.05). HDL cholesterol also decreased from 165 mg/dL to 130 mg/dL (nominal p<0.05).
Safety Profile and Limitations
ALN1003 (搜索) was generally well tolerated throughout both studies. The primary side effect observed was mild, short-term, reversible hypolocomotion in approximately half of dose administrations in the first study. In the second study, two mice in the high-dose group showed slight dehydration during the pharmacokinetic portion but otherwise appeared normal.
The company noted important limitations regarding the drinking water administration model, where ALN1003 (搜索) caused dose-related appetite and thirst reduction, potentially confounding the attribution of weight loss solely to drug exposure.
Development Strategy and Financial Position
"These early non-GLP data support ALN1003 (搜索)'s potential as a non-hormonal treatment to achieve meaningful body weight loss with favorable body composition changes and select liver-related findings," said Holger Weis, CEO of Alaunos. "We are focused on additional preclinical studies, optimizing formulations and refining manufacturing processes as we advance toward studies to enable an Investigational New Drug (IND) application."
The company's development roadmap includes additional preclinical studies to better understand ALN1003 (搜索)'s mechanisms, including measuring liver fat levels and scoring MASLD (搜索) severity. Alaunos has initiated a computational chemistry program to design and test ALN1003 variations to strengthen intellectual property and assess next-generation compounds.
As of September 30, 2025, Alaunos had approximately $1.9 million in cash and cash equivalents, with a runway extending into the second quarter of 2026. The company intends to pursue additional financing to support continued operations and advancement of its preclinical obesity (搜索) and metabolic program.